Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Amplified Breast Cancer”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Testing effectiveness (Phase 2)Looking for participantsNCT07288359
What this trial is testing

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals 205
Large-scale testing (Phase 3)Study completedNCT00005970
What this trial is testing

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Who this might be right for
Breast AdenocarcinomaHER2 Positive Breast CarcinomaStage IA Breast Cancer AJCC v7+4 more
National Cancer Institute (NCI) 3,436
Not applicableStudy completedNCT00535509
What this trial is testing

Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
King Faisal Specialist Hospital & Research Center 285
Testing effectiveness (Phase 2)Active Not RecruitingNCT04482309
What this trial is testing

T-DXd in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca 477
Testing effectiveness (Phase 2)Study completedNCT00958971
What this trial is testing

Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 43
Not applicableActive Not RecruitingNCT02455791
What this trial is testing

Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 43
Testing effectiveness (Phase 2)Looking for participantsNCT07220135
What this trial is testing

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

Who this might be right for
Breast Cancer
University of Kansas Medical Center 100
Testing effectiveness (Phase 2)Study completedNCT00721630
What this trial is testing

Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 24
Testing effectiveness (Phase 2)Ended earlyNCT05091528
What this trial is testing

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more
Silverback Therapeutics 2
Early research (Phase 1)Study completedNCT02650752
What this trial is testing

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

Who this might be right for
Metastatic Breast CancerCentral Nervous System (CNS) Metastases
Memorial Sloan Kettering Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT00591851
What this trial is testing

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 70
Testing effectiveness (Phase 2)Looking for participantsNCT05800275
What this trial is testing

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

Who this might be right for
Leptomeningeal MetastasisLeptomeningeal DiseaseHER2-positive Metastatic Breast Cancer
UNICANCER 30
Early research (Phase 1)Looking for participantsNCT07029399
What this trial is testing

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
HR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid Tumors+1 more
NiKang Therapeutics, Inc. 361
Testing effectiveness (Phase 2)Ended earlyNCT05163223
What this trial is testing

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Who this might be right for
Breast Cancer
Aston Sci. Inc. 10
Not applicableUnknownNCT02560311
What this trial is testing

Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis

Who this might be right for
ERBB2Breast CancerMetastatic Neoplasm
University of Zurich 100
Testing effectiveness (Phase 2)Looking for participantsNCT07193394
What this trial is testing

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer ( HER2 Negative)Unresectable Breast Cancer
Institut Curie 20
Testing effectiveness (Phase 2)WithdrawnNCT05041972
What this trial is testing

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Who this might be right for
HER2 Mutation-Related TumorsHER2 Amplified Solid Tumors
Ambrx, Inc.
Early research (Phase 1)Study completedNCT01097460
What this trial is testing

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Merrimack Pharmaceuticals 16
Testing effectiveness (Phase 2)Study completedNCT01111825
What this trial is testing

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Puma Biotechnology, Inc. 99
Testing effectiveness (Phase 2)Study completedNCT00356811
What this trial is testing

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 57
Next Page